Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 10 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Nucala — NUCALA
Application BLA125526 (BLA)
Imitrex — ZEMBRACE SYMTOUCH
Application NDA208223 (NDA)
Imitrex — ONZETRA XSAIL
Application NDA206099 (NDA)
Benlysta — BENLYSTA
Application BLA761043 (BLA)
Zejula — ZEJULA
Application NDA208447 (NDA)
Proair HFA — PROAIR DIGIHALER
Application NDA205636 (NDA)
Krintafel — ARAKODA
Application NDA210607 (NDA)
Krintafel — KRINTAFEL
Application NDA210795 (NDA)
Nucala — NUCALA
Application BLA761122 (BLA)
Imitrex — TOSYMRA
Application NDA210884 (NDA)
Brexafemme — BREXAFEMME
Application NDA214900 (NDA)
Jemperli — JEMPERLI
Application BLA761174 (BLA)
Ojjaara — OJJAARA
Application NDA216873 (NDA)
Zejula — ZEJULA
Application NDA214876 (NDA)
Jesduvroq — JESDUVROQ
Application NDA216951 (NDA)
EXDENSUR — EXDENSUR
Application BLA761458 (BLA)
BLENREP — BLENREP
Application BLA761440 (BLA)
Lamictal — SUBVENITE
Application NDA218879 (NDA)
Blujepa — BLUJEPA
Application NDA218230 (NDA)
Wellcovorin — VYKOURA
Application NDA220406 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)